TREATMENT OF MALADAPTIVE AGGRESSION IN YOUTH

T-MAY

The Rutgers CERTs Pocket Reference Guide
For Primary Care Clinicians and Mental Health Specialists

Copyright © 2010

Center for Education and Research on Mental Health Therapeutics (CERTs), Rutgers University, New Brunswick, NJ*
The REACH Institute (REsource for Advancing Children’s Health), New York, NY*
The University of Texas at Austin College of Pharmacy*
New York State Office of Mental Health
California Department of Mental Health

* This work was supported through the Agency for Healthcare Research and Quality cooperative agreement U18-HS016097, for the Center for Education and Research on Mental Health Therapeutics (S. Crystal, Rutgers University), with additional support from the Annie E. Casey Foundation to the REACH Institute (P. Jensen), the Texas Department of State Health Services, and the REACH Institute. Views expressed in this paper are those of the authors and do not necessarily reflect positions of the Agency for Healthcare Research and Quality, the Annie E. Casey Foundation, the REACH Institute, or participating agencies from Texas, New York, or California.
# TABLE OF CONTENTS

## INTRODUCTION
- T-MAY Steering Committee Statement 3
- T-MAY Recommendations 4

## ASSESSMENT + DIAGNOSIS
- BOLDER 6

## TREATMENT PLANNING + MANAGEMENT PLANNING
- PRESTO 8

## PSYCHOSOCIAL INTERVENTIONS
- The Family Collaboration Treatment Plan: 6 Basic Questions 11

## MEDICATION TREATMENTS
- Usual Medication Dosing and Titration Intervals of Antipsychotics (APs) 15
- Usual Medication Dosing and Titration Intervals of Mood Stabilizers (MSs) 17
- Footnotes: Liver Enzyme Inducers and Inhibitors 18

## SIDE EFFECT MANAGEMENT
- Relative Side-effects: Safety and Tolerability of Antipsychotics and Mood Stabilizers 20
- Relative Side Effects: Footnotes 21
- Strategies for the Management of Side effects to Antipsychotics and Mood Stabilizers 22

## MEDICATION MAINTENANCE + DISCONTINUATION
- Clinical Pearls of Side Effects Management 23
- Minimizing Side Effects When Switching Psychotropic Medications 23

## APPENDIX
- Algorithm For the Treatment of ADHD With Comorbid Aggression 25
- Algorithm For the Treatment of Depression/Anxiety With Comorbid Aggression 26
- Action Plans: Tips For Families 29
- Dietary and Physical Activity Recommendations 30
- AP Side-effects Checklist 31
- Clinical Global Impressions (CGI) 32
- Brief Psychiatric Rating Scale For Children (BPRS-C-9) 33
- Modified Overt Aggression Scale (MOAS) 35
- Young Mania Rating Scale 36

## BIBLIOGRAPHY
38
INTRODUCTION

Psychotropic agents, particularly second-generation antipsychotics and mood stabilizers, are increasingly prescribed to youth on an outpatient basis for the treatment of overt aggression, a symptom that may have multiple causes. These large-scale shifts in treatment practices have occurred despite potentially troubling side-effects and a lack of supportive empirical evidence. With the increase in the prescription of psychotropic agents outside of FDA-approved indications, concerns have been raised over treatment decision-making, appropriate use of alternative therapies, long-term management, safety of multiple drug regimens, and successful parental engagement and education. Given its indistinct etiology and variability in frequency and severity of symptoms, as well as the presence of overlapping comorbidities, treating and managing aggression is generally difficult and complex. To address this clinical need and improve outcomes for children and adolescents with maladaptive aggression, a steering committee was established to spearhead a consensus development and quality improvement initiative for clinicians treating such children and adolescents.

Through the collaboration of The REsource for Advancing Children’s Health Institute (REACH), the Center for Education and Research on Mental Health Therapeutics (CERTs) at Rutgers University, Columbia University/New York State Psychiatric Institute and participating national experts in the fields of policy, research, advocacy and child and adolescent psychiatry, the Treatment of Maladaptive Aggression in Youth (T-MAY) guidelines were developed. Under the direction of the T-MAY Steering Committee, the guideline development process involved: (1) extensive literature reviews; (2) an expert consensus survey to bridge existing gaps in the literature; (3) a two-day consensus conference involving content experts; and (4) successive refinement of the guidelines through further input from the T-MAY Steering Committee (cited below). The resulting T-MAY recommendations for diagnosis and assessment, treatment planning and side-effect management are the direct result of these partnered clinical and policy research efforts.*

The guidelines are intended for both primary care and specialty mental health prescribers. As such, T-MAY ultimately relies on physician expertise and discretion, and is not intended to undermine clinical judgment. Here, we present the companion “T-MAY Clinician’s Tool Kit,” a concise reference guide designed to aid clinicians in their implementation of T-MAY. This handbook provides a systematic, evidence-based treatment approach, but it represents only the first step in an ongoing process. Please contact us at the email addresses below with questions or suggestions. We are greatly interested in your feedback on the utility, format, and content of this guide.

Sherrie Bendele, B.S.
Alanna Chait, B.S.
Christoph Correll, M.D.
M. Lynn Crismon, Pharm.D.
Robert Findling, M.D.
Tobias Gerhard, Ph.D.
Cindy Gibson
Karen Hart, B.S.
Penelope Knapp, M.D.
Danielle Laraque, M.D.
Laurel K. Leslie, M.D., M.P.H.
John Lochman, Ph.D.
Judith A. Lucas, APN, Ed.D.
Matt Perkins, M.D.
Mark Olfson, M.D.
Elizabeth Pappadopuls, Ph.D.
Nancy Scotto Rosato, Ph.D.
Nancy Parker
Mark Wolraich, M.D.

*PeterJensen@TheReachInstitute.org
*contact for T-MAY manuscript preprints

Stephen Crystal, Ph.D.
Principal Investigator, CERTs
Rutgers University
doainfo@ifh.rutgers.edu
# T-MAY RECOMMENDATIONS

## ASSESSMENT + DIAGNOSIS

- Engage patients and parents (emphasize need for their on-going participation)
- Conduct a thorough initial evaluation and diagnostic work-up before initiating treatment
- Define target symptoms and behaviors in partnership with parents and child
- Assess target symptoms, treatment effects and outcomes with standardized measures

## INITIAL TREATMENT + MANAGEMENT PLANNING

- Conduct a risk assessment and if needed, consider referral to mental health specialist or ER
- Partner with family in developing an acceptable treatment plan
- Provide psychoeducation and help families form realistic expectations about treatment
- Help the family to establish community and social supports

## PSYCHOSOCIAL INTERVENTIONS

- Provide or assist the family in obtaining evidence-based parent and child skills training
- Identify, assess and address the child’s social, educational and family needs, and set objectives and outcomes with the family
- Engage child and family in maintaining consistent psychological/behavioral strategies

## MEDICATION TREATMENTS

- Select initial medication treatment to target the underlying disorder(s); follow guidelines for primary disorder (when available)
- If severe aggression persists following adequate trials of appropriate psychosocial and medication treatments for underlying disorder, add an AP, try a different AP, or augment with a mood stabilizer (MS)
- Avoid using more than two psychotropic medications simultaneously
- Use the recommended titration schedule and deliver an adequate medication trial before adjusting medication

## SIDE-EFFECT MANAGEMENT

- Assess side-effects, and do clinically-relevant metabolic studies and laboratory tests based on established guidelines and schedule
- Provide accessible information to children and parents about identifying and managing side-effects
- Use evidence-based strategies to prevent or reduce side-effects
- Collaborate with medical, educational and/or mental health specialists if needed

## MEDICATION MAINTENANCE + DISCONTINUATION

- If response is favorable, continue treatment for six months.
- Taper or discontinue medications in patients who show a remission in aggressive symptoms ≥ 6 months

---

*Note: The order of these recommendations may be tailored to each patient’s specific condition and needs.*
The check-list provides an essential overview of the T-MAY treatment guidelines developed through the process outlined in the introduction. The following pages of this section outline experts’ opinions as depicted in the flow diagram, entitled T-MAY Recommendations. Although understanding aggression as a multi-faceted symptom is the main focus of our guidelines, we also emphasize the importance of a thorough diagnostic work-up; assessment of relevant disorders and presenting behaviors of the child; engagement and collaboration of families in the treatment plan; and appropriate monitoring and evaluation of symptoms throughout the treatment process. For each step of the T-MAY approach, mnemonics, tools, strategies and charts are appended throughout. Information not embedded in the body of the text can be found in the appendices.

**ASSESSMENT AND DIAGNOSIS**

Given the multiple etiologies of aggression, as well as the variety of risk factors associated with outbursts, interpersonal aggression and oppositionality, a comprehensive assessment is necessary for understanding the development and context of maladaptive behaviors. Impulsive aggression is a symptom and treatment target in multiple childhood disorders, including Attention Deficit-Hyperactivity Disorder (ADHD), Conduct Disorder, Bipolar Disorder and Autistic Spectrum Disorders (including Pervasive Developmental Disorders). Assessments should carefully evaluate the child’s physical and cognitive functioning and include their performance and behavior in home, school and in other social, peer-dominated spheres. (Please see BOLDER following the T-MAY guidelines for assessment and diagnosis).

**ENGAGE PATIENTS AND PARENTS**

- Relationship-building can determine family and patient knowledge-base, identify perceived barriers to adherence to treatment, and affect the overall viability of the established treatment and management plan.
- Considerations of the family’s current level of stress, functioning status and beliefs about treatment should be clearly understood
- Get a clear picture of how they have attempted to deal with this overt aggression up to the point of your visit with them. Ask if they have reached out to other family members, community organizations, or other clinicians. If the answer is no, ask why they finally chose to seek medical treatment

**CONDUCT AN INITIAL EVALUATION AND PERFORM A DIAGNOSTIC WORK-UP BEFORE INITIATING TREATMENT**

- Identify the family’s concerns, and the reasons they are seeking treatment by contextualizing the target symptoms in terms of time/space/location. Include both the family and the child displaying overt aggression in your question-and-answer
- Determine their perceptions of the overt aggression: What is causing the aggressive symptoms to appear? Where do they occur mostly? What are the risks for injury of the child to self and others? What are their expectations for treatment? How do they want to be involved?
- To rule out potential contributory co-occurring symptoms or disorders which could have a significant effect on prognosis, all possible documentation of the child’s treatment history should be collected to grasp the character, intensity and frequency of target symptoms
- Using the DSM or ICD diagnostic criteria to assess other psychiatric or medical comorbidities is an essential first step in initiating treatment and management planning
- Assess target symptoms using available scales and rating tools (see appendix, please)
- Perform necessary diagnostic laboratory tests
ASSESS AND DEFINE TARGET SYMPTOMS AND BEHAVIORS IN PARTNERSHIP

- Assess the behavior of the child, towards him/herself and others.
- Determine the frequency and intensity of the symptoms, and how the child experiences them.
- Identify symptom exacerbants and coping mechanisms the child uses to counter the symptoms.
- Identify the symptoms of aggression that are most likely to respond to a specific treatment.
- Include the family’s input to ensure their participation throughout treatment and management planning.

B – BEHAVIOR: In what ways does the child exhibit aggression?

O – ONSET: When does it happen? What triggers it, and why?

L – LOCATION: Where do the symptoms occur – home/school?

D – DURATION: How long does it last?

E – EXACERBANTS: What makes it worse?

R – RELIEF: What makes it better?

BOLDER is a useful mnemonic to follow in the beginning stages of assessing and diagnosing a child with aggression. Use these questions to get a more complete understanding of the nature of the problem and to learn more about the child and the family you are working with. Be curious, and keep asking open-ended questions, such as “Can you tell me more about…”, or “What do you think about…”

Early during the initial assessment of a child with aggression, it is important to begin to form a team of mental health professionals, educators and advocates in the community who can help the family and participate with them in the treatment plan. To ensure their participation throughout the entire course of treatment, it is essential during this time that the clinician and the family work together to co-construct the treatment objectives and action plan.

Note: When youth exhibit signs of aggression, certain behavioral strategies such as cueing or prompting, verbal warnings, interventions, time away and time out can be effective. However, one should strongly consider a referral to a psychiatrist or to an emergency room, if 1) as a primary care physician, you do not feel comfortable providing care; or 2) the patient is a danger to him/herself or to someone else. Emergency medications may also need to be given; clinicians should be aware of a patient’s current medications and drug use in order to evaluate for the potential for drug-drug interactions.
TREATMENT PLANNING

Multiple factors are likely related to the onset and maintenance of aggression in children and adolescents with mental health disorders. These factors span a wide variety of domains, including inborn biological and genetic anomalies, the media, and larger socio-cultural forces, interactive family processes, school and community influences, limitations in the child’s cognitive, physical, social and communication skills, as well as other contributors from relationships with parents, caretakers and peers. Determining the most likely set of factors underpinning and eliciting the child’s aggression can be quite intricate, and often lie outside the scope of a single professionals’ area of expertise. (Please see PRESTO following T-MAY guidelines for treatment planning).

CONDUCT A RISK ASSESSMENT, GET REINFORCEMENTS AND REFER IF NEEDED

- When acute aggression is the cause of concern, the child and family must be carefully interviewed to determine the level and likelihood of physical risk the child presents others and to him/herself. Assessing the child’s intention to harm self or others, his/her degree of impulsivity, child and family history of aggression, family parenting style, and the parents’ methods of reward and punishment can help to ascertain the appropriate information about the frequency, duration, triggers, and risk of the child’s aggressive behaviors.
- In addition to the family dynamic, special attention should be paid to determining the impact of the child’s social network, and the potential role of drug and/or alcohol use/abuse in inciting aggression.
- Given the varied environmental and psychiatric contexts in which aggression can occur, clinicians are encouraged to identify potential obstacles from their on-going collection of data, to optimize treatment conditions.

PROVIDE PSYCHOEDUCATION AND SET REALISTIC EXPECTATIONS ABOUT TREATMENT

- Engaging patients and their families from the start of the assessment phase better ensures their openness to participating in dialogues about impulsive aggression, DSM disorders that may be present and strategies to manage the child’s behavior.
- Clinicians should seek to maximize communication and effective learning by first inquiring about parents’ and children’s pre-existing concerns, beliefs and understandings about the causes, consequences and interventions for aggression. If assumptions are invalid or myth-based, providers should make complete, easy-to-read information materials available in the family’s preferred language and format.
- In order for families to fully understand the risks, benefits and trade-offs involved in addressing aggression, information should include (1): what is known about the causes of aggression; (2) consequences if not addressed; (3) the various environmental, psychosocial and medication interventions available; (4) types of medical and educational assistance the family can receive; (5) sources of culturally-appropriate family support, and additional services and outlets for information in the local community.
- Outlining the family’s and community’s role in this way can significantly impact the patient-clinician relationship, treatment adherence and outcomes in an optimistic and constructive way.

HELP THE FAMILY TO ESTABLISH COMMUNITY AND SOCIAL SUPPORTS

- Developing an appropriate treatment plan with the patient and family should take into account their concerns, fears, and expectations. Similarly, specific treatment goals in key areas of functioning should be agreed upon by family members.
- Plans for the short-term, long-term, and emergency situations, are all equally important and deserve coordination. It is essential that a crisis plan be co-developed with the family that outlines how emergency situations should be handled. Identifying potential in-patient and out-patient clinical services and discussing the roles of parents and clinical providers are key elements to plan for when preparing the family for imminent distress.
Finding the right professional can be more difficult if family is economically disadvantaged, or lives in a geographically-isolated region. You should provide the referrals for the family (if necessary) to primary care physicians, insurance companies, local hospitals and universities, and/or appropriate professional associations.

It is also important to refer families to relevant resources in the community, including parent advocates and relevant family support groups, to assist them in their coping with disruptions in the family dynamic, and to learn about how to access educational and health care services that can procure stability.

ASSESS TREATMENT EFFECTS AND OUTCOMES WITH STANDARDIZED MEASURES

A comprehensive assessment of aggression is necessary for symptom identification, and for successfully treating and managing the symptoms; above all, it is relevant to identify the limitations and barriers to the child’s achievement in following a specific, recommended regimen. Over the course of the assessment, and following diagnosis, it is important to continually track and reassess aggression problems to verify the adequacy of the treatment response.

Screening and assessment tools to characterize and/or quantify symptoms can serve as benchmarks of treatment progress and provide insights during monitoring of psychotropic medications. Rating scales vary according to their data-gathering style, content, time-frame, and scale. Most importantly, they should be culturally-appropriate, valid and reliable to promote feedback from the family and child.

Additional copies of the T-MAY toolkit can be downloaded without cost or ordered in print form at cost at www.t-may.org.

During follow-up visitations with the patient and family, clinicians should evaluate environmental factors and/or changes that may improve or worsen the child’s symptoms and determine adherence to prescribed treatment. Collecting family insights can aid in this level of surveillance.

P – PARTNER with the family

R – Assess RISK identify professional REINFORCEMENTS, and REFER if need be

E – EDUCATE the family on evidence-based practices and expectations of treatment

S – Ascertain SUPPORT in the community

T – TRACK signs and symptoms with tools

O – OBJECTIVES and Action Plans are established with the family

Note: BOLDER and PRESTO have been designed to positively influence critical thinking throughout the assessment and diagnosis and treatment planning. The above framework establishes the platform for the entire document. For each of the five processes of the T-MAY approach, mnemonics, guidelines, strategies and charts are appended throughout. Information not embedded in the body of the text can be found in the appendices.
PSYCHOSOCIAL INTERVENTIONS

Although a variety of medications show substantial efficacy in reducing aggression associated with different primary conditions (Schur et al., 2003; Turgay et al., 2002; Croonenberghs et al., 2005; Findling et al., 2004; Greenhill et al., 1985), evidence for the successful management of aggression in youth includes the provision of psychoeducation, and setting realistic expectations about treatment with the patient and family. Techniques such as Parent-Management Training, School-Based Social Skills Training and general prevention programs have shown efficacy in reducing aggression (Tremblay et al., 1995; Kellam et al., 1994), promoting positive, pro-social and compliant behavior in children and encouraging parents to adopt more consistent and predictable child-management strategies (Patterson, 1982; Patterson et al., 1992; Webster-Stratton and Spitzer, 1996). Proper management of anger can lead to reduced number of incidents of physical aggression and improved parent and teacher ratings of behavior.

Identifying and organizing yourself through performing a thoughtful and thorough evaluation and diagnosis has allowed you to identify and organize your thoughts and potential concerns. Having gotten to know the family better, you and the family can move on to the next phase: using innovative problem-solving and collective wisdom to tackle aggression with practical application and predication. For younger children, multimodal treatment plan approaches that involve parent and child training and/or therapy have demonstrated the greatest efficacy in managing persistent aggressive behaviors. During our literature review, it became apparent that certain evidence-based treatments were more likely to be used with older children and families with younger children. This is not unusual, given that age and developmental level of the child contribute significantly to the decision of which treatment modality to employ.

PROVIDE OR ASSIST THE FAMILY IN OBTAINING EVIDENCE-BASED INFORMATION

- It is important for families to feel as if their efforts up to the point of requesting your help (the help of a physician) have not been in vain. Most parents have read available books, sought out the advice of a professional counselor or therapist, have had repeated discussions with their child’s teachers, and have spoken to family and friends about the impact aggression has on their and the child’s life.
- Creating a good life and crafting a promising future for a child with aggression is incredibly complicated, and will require trial and error. Clinicians should seek to maximize communication and effective learning by first inquiring about parents’ and children’s pre-existing concerns, beliefs and understandings about the causes, consequences and interventions for aggression.
- If assumptions are invalid or myth-based, providers should make complete, easy-to-understand information materials available in the family’s preferred language and communication format. In order for families to fully understand the risks, benefits, and trade-offs involved in addressing aggression, information should include (1): what is known about the causes of aggression; (2) consequences if not addressed; (3) the various environmental, psychosocial, and medication interventions available; (4) types of medical and educational assistance the family can receive; (5) sources of culturally-appropriate family support and additional services and outlets for information in the local community. Some individuals may prefer visual learning materials (i.e., DVDs, videotapes, and videostreams) over written materials.

ASSESS AND ADDRESS THE CHILD’S SOCIAL, MEDICATION, EDUCATIONAL AND FAMILY NEEDS

- Though relying on what you know is helpful, it is necessary to work alongside the family to debug those standardized techniques and apply the tools in a way that is appropriate for the circumstance, in “real life.”
- Please see the Family Collaborative Plan: six basic questions to be answered by the clinician, child and family.
• Please see the *Psychosocial Treatment Planning and Management of Overt Aggression for Families and Clinicians*, a template to develop short-term, intermediate, and long-term action plans to manage and monitor the treatment of overt aggression.

**ENGAGE CHILD AND FAMILY IN MAINTAINING CONSISTENT PSYCHOLOGICAL/BEHAVIORAL STRATEGIES**

• Each family has to make treatment decisions based on the available resources and what makes the best sense for their child.
• Emphasize the family’s need for on-going family and community support.
• Treating aggression requires flexibility in planning; prepare the family for multiple changes likely to be needed throughout treatment.
Dispensing what seems like simple, typical medical advice isn’t always enough to send a family home fully-equipped with taking on something as perplexing and inroad as aggression. The difference between what can be read in any information booklet (no matter how adept the reader is or how comprehensive the narrative) and what works to counter aggression in the “real world,” lies in the particulars of adapting the advice to the given circumstances of that child and family. A “one-size-fits-all” treatment, whether or not it’s coupled with sophisticated pharmaceuticals, will not get at the underlying sources of the aggression.

6 BASIC QUESTIONS:

1 – WHO is/are the active agent(s) (physician, therapist, caregiver, teacher, patient etc.)?

2 – WHAT is the treatment goal? What therapeutic modality is going to be used?

3 – WHERE is the treatment being given? Is it location-specific?

4 – WHY is the patient being treated? Which symptom(s) are targeted?

5 – WHEN is therapy given?
   WHEN should medication be administered?

6 – HOW MANY sessions of therapy are suggested over determined period of time?
   HOW MUCH medication (dose) is prescribed?

The 6 Basic Questions outline a series of questions that can help parents, children in treatment, and doctors to standardize their efforts towards preventing the symptoms of aggression to arise. By establishing answers to the above questions as a collaborative, compliance to treatment is more likely to be successful. Though the Family Collaborative Plan may appear at first-glance as a “cookbook” outline, it is necessary that you keep in mind that the answers to these 6 Basic Questions may change over the course of treatment. It would be wise to get into the practice of answering these questions each and every time you meet with the family to avoid confusion.

Action Plans, along with the Family Collaborative Plan, help to promote long-term vision and short-term motivation for treatment planning and management of side-effects. Treating aggression is often challenging, but short-, intermediate- and long-term planning can keep everyone focused on organizing resources, meeting the family’s needs and ensuring that all parties have a clear awareness of what they must do in order to help the child in treatment achieve a particular objective or outcome.
### ACTION PLANS: PSYCHO-SOCIAL TREATMENT PLANNING + MANAGEMENT OF OVERT AGGRESSION FOR FAMILIES AND CLINICIANS

A Template to Develop Short-, Intermediate- and Long-term Action Plans to Manage and Monitor Treatment of Overt Aggression

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADDRESSING NEEDS + IDENTIFYING RESOURCES</td>
<td>How will the need(s) be addressed? What resources are available?</td>
<td>Who is the active agent?</td>
<td>Is treatment location- and time specific?</td>
<td>What is the time-frame?</td>
<td>How many sessions of therapy are suggested?</td>
<td>Why is the action important?</td>
</tr>
<tr>
<td>SOCIAL + EMOTIONAL: IMPROVING SELF-ESTEEM</td>
<td>Learn origami; buy fun paper and find a “how-to” book</td>
<td>Parents/Guardians and Child</td>
<td>Dining Room Table or a community-offered class</td>
<td>Weekend Afternoons</td>
<td>1-2 times a week</td>
<td>Developing a skill or hobby can increase interest, dedication, and a feeling of accomplishment.</td>
</tr>
<tr>
<td>MAKING FRIENDS</td>
<td>Discuss with teacher; express your concerns and expectations</td>
<td>Parents/Guardians &amp; Teacher May want to discuss with other parents</td>
<td>At the School</td>
<td>Before or After School</td>
<td>Discuss once a week; ask child everyday about the children at School</td>
<td>Can facilitate learning from peers + shared experiences. Can also facilitate More positive social interactions; increased planned activities with other students.</td>
</tr>
<tr>
<td>MEDICAL NEEDS: MAKING THE MOST OF MEDICINE</td>
<td>Determine if prescribed med regimen is best + document what you notice</td>
<td>Child Parents/Guardians Teacher and Doctor</td>
<td>At Home At School At the doctors office</td>
<td>In the AM In the afternoon At night</td>
<td>Chart sleep and behavioral patterns daily; discuss with doctor monthly.</td>
<td>Finding the best type and dose of medication will result in fewer or no side-effects, and improve overall physical, social and mental well-being.</td>
</tr>
<tr>
<td>MONITORING SIDE-EFFECTS</td>
<td>Read up to learn about side-effects + document changes in behavior/mood</td>
<td>Child Parents/Guardians Teacher and Doctor</td>
<td>Go to high quality websites for information + find local sources in the community</td>
<td>Record changes in mood + behavior. Report drastic changes to doctor ASAP</td>
<td>Chart sleep and behavioral patterns daily; discuss with doctor monthly.</td>
<td>Monitoring side-effects will help you to discern whether or not medication is working for your child.</td>
</tr>
<tr>
<td>EDUCATIONAL NEEDS: PERFORMANCE IN SCHOOL</td>
<td>Better understand your child’s academic strengths + weaknesses</td>
<td>Parents/Guardians</td>
<td>At School with the Teacher</td>
<td>Start immediately; it’s best to start at the beginning of the school week.</td>
<td>Request a weekly Progress Report to track behavior + learning (e.g., test scores)</td>
<td>Understanding your child's apprehension, perceived hardship and attitudes toward learning can help you to identify new ways to make learning fun and exciting. Alleviating the stressors of school can improve overall time at the kitchen table.</td>
</tr>
<tr>
<td>DOING HOMEWORK</td>
<td>Discuss and develop a HW plan to address assignment load</td>
<td>Parents/Guardians and Child</td>
<td>At the kitchen table</td>
<td>After school and, on weekends</td>
<td>Every day/week</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-------</td>
<td>-----------</td>
<td>------</td>
</tr>
<tr>
<td><strong>CHILD IN TREATMENT</strong></td>
<td>Make the child feel good about the extra time you spend with him/her</td>
<td>Parents/Guardians, Siblings, Teacher</td>
<td>At Home, During Activities, At School</td>
<td>All the time</td>
<td>Positive feedback and praise should be given as much as possible</td>
<td>Raising a child that requires special attention and additional time, especially when there are other children in the family, can be difficult on everyone.</td>
</tr>
<tr>
<td><strong>PARENTS</strong></td>
<td>Each should have time alone; parents must both agree on action plans + reward system</td>
<td>Parents/Guardians</td>
<td>Go out, or stay in</td>
<td>Discuss your needs with the children, and family or sitter</td>
<td>At least once a week</td>
<td>Strong intra-family communication is key to maintenance + progress.</td>
</tr>
<tr>
<td><strong>SIBLINGS</strong></td>
<td>Spend quality time with other siblings. Express concern for their health, too</td>
<td>Parents/Guardians &amp; Siblings</td>
<td>Let the siblings decide; show interest in their hobbies + social events</td>
<td>As much as possible. You can formalize plans on a weekly basis.</td>
<td>At least once a week</td>
<td>Including everyone in the action plans, spending individual time with family members, and taking time for yourself, is key to decreasing conflicts in the home, and preventing feelings of negligence, burnout or burden.</td>
</tr>
<tr>
<td><strong>FAMILY AS A WHOLE</strong></td>
<td>Include your children in planning activities where everyone is included</td>
<td>Parents/Guardians, Siblings, Child in Treatment</td>
<td>Decide as a group</td>
<td>Meet as a group to develop the family calendar. It should be in view + revisable.</td>
<td>Once a week, or twice a month</td>
<td></td>
</tr>
</tbody>
</table>


Note: This chart is helpful in that it provides examples of how to establish short-term, intermediate, and long-term outcomes and goals with the child and family. A blank copy can be found in the appendix for repeated use.
MEDICATION TREATMENTS

Psychotropic agents, particularly second-generation antipsychotics and mood stabilizers, are increasingly prescribed to youth on an outpatient basis for the treatment of overt aggression, a symptom that may have multiple causes. These large-scale shifts in treatment practices have occurred despite potentially troubling side-effects and a lack of supportive empirical evidence of their effects on adolescents and children; a large part of the information existing on antipsychotics and mood stabilizers have been extrapolated from adult populations. Therefore, information may change as more data from large pediatric populations become available. As the T-MAY guidelines suggest, treatment planning should consider a multimodal approach. Education of the parents and child and forming a team of health care professionals is just as important in this phase of treatment as it is during previous ones. Their input will help you to better understand the potential for unexpected risks and benefits and may result in more appropriate monitoring of patients.

SELECT INITIAL MEDICATION TREATMENT TO TARGET THE UNDERLYING DISORDER(S)

- Treatment planning should consider severity and impairment of the aggression and take into consideration both symptom reduction and functional impairment.
- Doses need to be individualized based on efficacy and tolerability.
- Follow guidelines for primary disorder (when available). Please see the T-MAY Recommendations (p. 4).

IF RESPONSE IS INADEQUATE

- Avoid using more than two psychotropic medications simultaneously.
- Assessing symptoms and functioning at home, at school and among peers should be systematic and regular.
- Add an AP, try a different AP, or augment with a mood stabilizer (MS).
- Please see the Typical Medication Dosing and Titration Intervals of Antipsychotics (p. 15) and Mood Stabilizers (p. 17).

BEFORE ADJUSTING MEDICATION

- Please see the T-MAY Guidelines (p. 4), General Rules for Switching Psychotropic Medications (p. 23), and Clinical Pearls For Switching Psychotropic Medications (p. 23).
### Usual Medication Dosing and Titration Intervals of Antipsychotics (APs) *

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Dose Range (mg)</th>
<th>Dose Strength (mg)</th>
<th>Medication Formulations (available for use)</th>
<th>Starting Dose (mg)</th>
<th>Half Life (hrs)</th>
<th>Time to Peak (hrs)</th>
<th>Titration Intervals (days)</th>
<th>Principal Liver Enzyme</th>
<th>Liver Enzyme Inducer</th>
<th>Liver Enzyme Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Second Generation Antipsychotics (SGA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Aripiprazole (ARI)</strong></th>
<th>Child: 2.5 - 15</th>
<th>2, 5, 10, 15, 20, 30; 10, 15, liquid 1 (30 mg = 25 mL)</th>
<th>po, im short, dis., liquid</th>
<th>2 to 5</th>
<th>50 to 72</th>
<th>3 to 5</th>
<th>when starting at 2mg, may increase dose every 3rd day; after steady state, increase dose every 7-14 days</th>
<th>2D6 &gt; 3A4</th>
<th>3A4</th>
<th>2D6 3A4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clozapine (CLO)</strong></td>
<td>Child: 150 - 300</td>
<td>25; 100</td>
<td>po</td>
<td>12.5</td>
<td>12</td>
<td>1 to 4</td>
<td>25 mg daily or, every other day</td>
<td>1A2&gt;2C19 2C19&gt;3A4 3A4&gt;2C9 2C9&gt;2D6</td>
<td>1A2 2C19 3A4 2A2 2C19 3A4 2C9</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Olanzapine (OLA)</strong></td>
<td>N/A</td>
<td>5, 5, 7.5, 10, 15, 20 tbl; 5, 10, 15, 20 dis; 10im</td>
<td>po, im short, dis.</td>
<td>5 to 10</td>
<td>30</td>
<td>6</td>
<td>increase at intervals &gt; 5 days</td>
<td>1A2</td>
<td>2D6</td>
<td>3A4</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Paliperidone (PAL)</strong></td>
<td>3 to 12</td>
<td>3, 6, 9</td>
<td>po, ER</td>
<td>3</td>
<td>21 to 30</td>
<td>24</td>
<td>increase at intervals &gt; 5 days</td>
<td>&lt;10% Hepatic Clearance</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Quetiapine (QUE)</strong></td>
<td>150 to 750</td>
<td>25, 100, 200</td>
<td>po, XR</td>
<td>50-100 IR 200-300 XR</td>
<td>6 to 7</td>
<td>2</td>
<td>100 mg per day</td>
<td>3A4</td>
<td>3A4</td>
<td>3A4</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Risperidone (RIS)</strong></td>
<td>Child: 1.5 - 2</td>
<td>0.5, 1, 2, 3, 4 tablets; 0.5, 1, 2 dis; liquid 1mg/mL 30ml bottl</td>
<td>po, im long, dis., liquid</td>
<td>0.5 to 1</td>
<td>3</td>
<td>1 to 2</td>
<td>increase at intervals of 0.5-1 per day or &gt; 5 days</td>
<td>2D6 &gt; 3A4</td>
<td>2D6 3A4</td>
<td>2D6 3A4</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Ziprasidone (ZIP)</strong></td>
<td>80 to 160</td>
<td>20, 40, 60, 80 tablets</td>
<td>po im short</td>
<td>20 to 40</td>
<td>7</td>
<td>5</td>
<td>increase at 20-40 per day</td>
<td>Aldehyde Oxidase &gt; 3A4</td>
<td>3A4</td>
<td>3A4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ANTIPSYCHOTIC</th>
<th>DOSE RANGE (mg)</th>
<th>DOSE STRENGTH (mg)</th>
<th>MEDICATION FORMULATIONS (available for use)</th>
<th>STARTING DOSE (mg)</th>
<th>HALF LIFE (hrs)</th>
<th>TIME TO PEAK (hrs)</th>
<th>TITRATION INTERVALS (days)</th>
<th>PRINCIPAL LIVER ENZYME</th>
<th>LIVER ENZYME INDUCER</th>
<th>LIVER ENZYME INHIBITOR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FIRST GENERATION ANTIPSYCHOTICS (FGA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HALOPERIDOL (HAL)</td>
<td>1 to 6</td>
<td>0.5, 1, 2, 5, 10, 20 tablets, 2; 10 mg/mL liquid, 5 im</td>
<td>po, im short im long</td>
<td>0.25-1</td>
<td>3 - 6 po</td>
<td>2-6 po</td>
<td>increase dose by 0.5 kg intervals of 5-7 days</td>
<td>3A4</td>
<td>3A4</td>
<td>3A4</td>
</tr>
<tr>
<td>MOLINDONE (MOL)</td>
<td>20 to 140</td>
<td>5, 10, 25, 50</td>
<td>po</td>
<td>0.5-1 mg/kg/d divided in 3-4 doses</td>
<td>1.5</td>
<td>1.5</td>
<td>N/A</td>
<td>2D6</td>
<td>2D6</td>
<td>2D6</td>
</tr>
<tr>
<td>PERPHENAZINE (PER)</td>
<td>8 to 32</td>
<td>2, 4, 8, 16</td>
<td>po</td>
<td>TBD; no data available Chlorpromazine Dose ≈ 10 mg</td>
<td>8 to 12</td>
<td>1 to 3</td>
<td>TBD; no data available</td>
<td>2D6</td>
<td>2D6</td>
<td>2D6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MOOD STABILIZER</th>
<th>DOSE RANGE (mg)</th>
<th>DOSE STRENGTH (mg)</th>
<th>MEDICATION FORMULATIONS (available for use)</th>
<th>STARTING DOSE (mg)</th>
<th>HALF LIFE (hrs)</th>
<th>TIME TO PEAK (hrs)</th>
<th>TITRATION INTERVALS (days)</th>
<th>PRINCIPAL LIVER ENZYME</th>
<th>LIVER ENZYME INDUCER</th>
<th>LIVER ENZYME INHIBITOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBAMAZEPINE</td>
<td>100 - 800</td>
<td>100, 200, 100 mg/5mL</td>
<td>po</td>
<td>100 mg B.I.D. (tbl), 1/2 tsp QID (susp) for 6-12 years</td>
<td>Initial 25 - 65 Later 12 to 17</td>
<td>4 to 5</td>
<td>Add &lt; 100 mg/day at weekly intervals, t.i.d or q.i.d. (tbl) till optimal response</td>
<td>3A4&gt;2D6 2D6.1A2 Auto-Inducer</td>
<td>3A4 2D6 1A2</td>
<td>3A4 2D6 1A2</td>
</tr>
<tr>
<td>CARBAMAZEPINE</td>
<td>100 - 800</td>
<td>100, 200, 400</td>
<td>po</td>
<td>100 mg for 6-12 years B.I.D. or T.I.D.</td>
<td>Initial 25 - 65 Later 12 to 17</td>
<td>3 to 12</td>
<td>Add 100 mg/day at weekly intervals b.i.d until optimal response</td>
<td>3A4&gt;2D6 2D6.1A2 Auto-Inducer</td>
<td>3A4 2D6 1A2</td>
<td>3A4 2D6 1A2</td>
</tr>
<tr>
<td>DIVALPROEX</td>
<td>500 - 2000</td>
<td>125, 250, 500</td>
<td>po</td>
<td>10 - 15 mg/kg/d B.I.D. or T.I.D.</td>
<td>9 to 16</td>
<td>3 to 4</td>
<td>Add 5-10 mg/kg/day q 7 days; give with food. Increase rapidly to lowest effective dose</td>
<td>CYP450 C29 (weak inhibitor)</td>
<td>Rifampin Secobarbital</td>
<td># please see footnote</td>
</tr>
<tr>
<td>DIVALPROEX</td>
<td>500 - 2000</td>
<td>250, 500</td>
<td>po</td>
<td>10-15 mg/kg/day po</td>
<td>9 to 16</td>
<td>7 to 14</td>
<td>Increase dose by 5 - 10 mg/kg/wk until optimal response; clinical response is at plasma levels of 85-125 µg/mL</td>
<td>CYP450 C29 (weak inhibitor)</td>
<td>Rifampin Secobarbital</td>
<td># please see footnote</td>
</tr>
<tr>
<td>LAMOTRIGINE</td>
<td>50 - 200</td>
<td>25, 100, 150, 200</td>
<td>po</td>
<td>only 25mg &lt; 16 yo, or on DVP</td>
<td>24 - 34</td>
<td>1.4 - 4.8</td>
<td>dose stable for 2 wks, increase by 12.5 - 25 mg; but if &lt; 16 yo, or on DVP, increase by 12.5 mg</td>
<td>Glucuronidation</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>LITHIUM</td>
<td>600 - 1800</td>
<td>8mEq/5mL</td>
<td>po</td>
<td>15 - 20 mg/kg/d B.I.D. or T.I.D.</td>
<td>20 - 24</td>
<td>1 to 3</td>
<td>Dose wkly based on plasma Li+ levels</td>
<td>Renal Elimination Only</td>
<td>Renal Elimination Only</td>
<td>Renal Elimination Only</td>
</tr>
<tr>
<td>LITHIUM CR</td>
<td>1800 mg/d; serum level 1-1.5mEq/L adults</td>
<td>300, 450</td>
<td>po</td>
<td>150 - 300 mg B.I.D.</td>
<td>24</td>
<td>4</td>
<td>Dose according to need</td>
<td>Renal Elimination Only</td>
<td>Renal Elimination Only</td>
<td>Renal Elimination Only</td>
</tr>
</tbody>
</table>

**FOOTNOTES: TYPICAL MEDICATION DOSING AND TITRATION INTERVALS OF ANTIPSYCHOTICS + MOOD STABILIZERS**

### *LIVER ENZYME INDUCERS*

1A2: Smoking; Carbamazepine (weak)
2C9: Rifampin; Secobarbital
2C19: Carbamazepine; Norethindrone; Prednisone; Rifampin
2D6: Carbamazepine (high doses)
3A4: Carbamazepine; Phenytion; Phenobarbital; Rifampin; St. John’s Wort

### *LIVER ENZYME INHIBITORS*

1A2: Fluvoxamine; Omeprazole; Grapefruit Juice
2C9: Fluconazole; Amiodarone; Fenofibrate; Fluvasitatin; Fluvoxamine; Isoniazid; Lovastatin; Phenylbutazone; Probenicid; Sertraline; Sulfamethoxazole; Sulphaphenazole; Teniposide; Voriconazole; Zafirlukast
2C19: Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Chloramphenicol; Cimetidine; Felbamate; Fluoxetine; Fluvoxamine; Indomethacin; Ketoconazole; Modafinil; Oxacarbazepine; Probenicid; Ticlopidine; Topiramate
2D6: Bupropion; Fluoxetine; Paroxetine; Terbinafine; Quinidine
3A4: Clarithromycin; Erythromycin; Fluconazole; Fluvoxamine; Indinavir; Itraconazole; Ketoconazole; Nelfinavir; Nefazodone; Ritonavir; Grapefruit Juice

### NOTES

* A large part of the data is extrapolated from adult populations. Therefore, information contained in the table may change as more data from large pediatric populations become available.

a - Doses need to be individualized based on efficacy and tolerability.

b - Average dose range provided for adolescents with schizophrenia or bipolar disorder; for prepubertal patients or those with other diagnoses, average dose may be approximately 33% to 50% lower.

# - Divalproex levels may be increased when combined with the following medications: Fluconazole; Amiodarone; Fenofibrate; Fluvasitatin; Fluvoxamine; Isoniazid; Lovastatin; Phenylbutazone; Probenicid; Sertraline;

Children on psychotropic medications should be seen by their prescribing clinician no less than once every three months. This is a bare minimum. Children in acute settings, who display unsafe behavior, experience significant side-effects, or do not respond to medication trials, or are in an active phase of a medical trial should be seen more frequently.

If laboratory tests are indicated to monitor therapeutic levels of a medication or to monitor potential organ system damage from a medication, these lab studies should be performed every three months at a minimum (maintenance phase). If the medication is being initiated, these lab tests should be performed more frequently until a baseline is achieved.

N/A = Not applicable; No Data Available.

B.i.D. - *bis in die*, a direction to take medication twice daily

diss. - dissolvable

ER - extended release

im short/long - medication is delivered by intramuscular injection

IR - immediate release

liquid - medication comes in liquid form, and taken by mouth

mEq - milliequivalent

po - *per orem*, a direction to take a medication by mouth

T.I.D. - *ter in die*, a direction to take medication three times daily

TBD - to be determined; data not yet available

XR - extended release
SIDE EFFECT MANAGEMENT

Having established a strong working relationship with the family members will help to monitor the effect each medication has on the child’s aggression, and overall well-being. Methods for managing side effects are done on a case-by-case basis, given the need to consider family concerns, tolerability, efficacy, and because each child’s response profile will be unique. Even as more data become available from large pediatric populations, it is unlikely that the implementation of successful treatment plans will ever be standardized. Assessing and managing clinically-relevant side-effects require that the tending physician, family and child are aware of the benefits and risks of each medication to effectively utilize pharmacological approaches for clinical aggression.

ASSESS CLINICALLY-RELEVANT SIDE EFFECTS

- In general, there is a direct, positive relationship between dose and adverse effect(s), and use of more than one antipsychotic (AP) increases the risk for AP-related side-effects.
- Studies and tests based on established guidelines should be used whenever available.
- If laboratory tests are indicated to monitor therapeutic levels of a medication or to monitor potential organ system damage from a medication, these lab studies should be performed every three months at a minimum (maintenance phase). If the medication is being initiated, these lab tests should be performed more frequently until a baseline is achieved.

PROVIDE ACCESSIBLE INFORMATION ABOUT IDENTIFYING AND MANAGING SIDE EFFECTS

- Educating the parent and child about the known side effects of antipsychotics and mood stabilizers helps provide them with the knowledge to monitor improvements and identify medication side effects.
- Please see Relative Side Effects: Safety and Tolerability of Antipsychotics and Mood Stabilizers (p. 20).

USE EVIDENCE-BASED STRATEGIES TO PREVENT OR REDUCE SIDE EFFECTS

- Reducing and preventing side effects is important to avoid unintended consequences of medication.
- Please see Strategies for the Management of Relative Side Effects to Antipsychotics (AP) + Mood Stabilizers (MS) (p. 22).

COLLABORATE WITH MEDICAL, EDUCATIONAL AND/OR MENTAL HEALTH SPECIALISTS

- Identify integral players in the treatment and assign them roles.
- Response to treatment cannot be adequately monitored by using clinical interview and clinical judgment alone.
- Finding the best treatment plan requires the mobilization of existing resources as well as mobilizing your existing resources. Family members and other professional caregivers can help you find the most appropriate, effective treatment for each unique child.
# RELATIVE SIDE-EFFECTS: SAFETY + TOLERABILITY OF ANTIPSYCHOTICS AND MOOD STABILIZERS

Comparative Overview of Side-effect Profiles of Second- and First-Generation Antipsychotic Medications and Mood Stabilizers

<table>
<thead>
<tr>
<th>ADVERSE EFFECT(S)</th>
<th>TIME COURSE</th>
<th>DOSE DEPENDENCY</th>
<th>SECOND-GENERATION ANTIPSYCHOTICS (SGA)</th>
<th>FIRST-GENERATION</th>
<th>MOOD STABILIZERS (MS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACUTE PARKINSONISM</td>
<td>Early</td>
<td>+++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>AKATHISIA</td>
<td>Early/Inter-</td>
<td>+++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>DIABETES</td>
<td>Late</td>
<td>+ ?</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>↑ LIPIDS</td>
<td>Early/Inter-</td>
<td>0?</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>NEUTROPENIA</td>
<td>First 6 mo.</td>
<td>+ ?</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>ORTHOSTASIS</td>
<td>Early/Titration</td>
<td>+++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>↑ QT c INTERVAL</td>
<td>Early/Titration</td>
<td>+ ?</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>SEDATION</td>
<td>Early/ May Improve</td>
<td>+++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>SEIZURES</td>
<td>During Titration</td>
<td>+++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>STEVEN'S JOHNSON SYNDROME (SERIOUS); RASH</td>
<td>High Start Dose; Fast Titration</td>
<td>++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>TARDIVE DYSKINESIA</td>
<td>Late</td>
<td>++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>WITHDRAWAL DYSKINESIA</td>
<td>Early Taper Fast Switch</td>
<td>+++</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
<tr>
<td>WEIGHT GAIN</td>
<td>First 3-6 Months</td>
<td>0?</td>
<td>ARI + CLO OLA PAL QUE RIS ZIP HAL MOL PER</td>
<td>CBZ* LIT LTG VP*</td>
<td></td>
</tr>
</tbody>
</table>


FOOTNOTES: RELATIVE SIDE-EFFECTS FOR SGAs, FGAs and MOOD STABILIZERS

Comparative Overview of Side Effect Profiles

+ - +++ There is a (low to high) direct, positive relationship between dose and adverse effect(s)

a - There is insufficient long-term data to fully determine the risk

b - Unlikely due to low risk factors in childhood and adolescents, and long lag time for cerebrovascular disease to develop

c - Less at higher doses (? Above 250 mg/day)

d - Relevance for the development of torsade de points not established

e - Less than 1% per year in adults who were often pre-treated with FGAs

f - Of unclear clinical relevance

g - (1) Hyponatremia/SIADH is evident with Carbamazepine (CBZ); the dose dependency is +

h - (2) Hypothyroidism is evident with Lithium (LI); the dose dependency is +++

i - (3) Hyperparathyroidism is evident with mood stabilizers: Carbamazepine (CBZ); Lithium (Li); and Valproic Acid (VP); the dose dependency is + for each

j - (4) Polycystic ovaries occurred in 1090 of young adults women treated with Valproic Acid (VP) for a year

* A large part of the data is extrapolated from adult populations. Therefore, information contained in the table may change as more data from large pediatric populations become available

* Use of more than one AP increases the risk for AP-related side-effects
<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>POTENTIAL SIDE-EFFECTS</th>
<th>FIRST-LINE OPTIONS (Not necessarily in order of priority)</th>
<th>ALTERNATIVE CONSIDERATIONS (Not necessarily in order of priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Cholinergic</td>
<td>Constipation: High fiber diet; Give fluids; Bulk laxatives or stool softener; Decrease dose</td>
<td>Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dry Mouth: Give sugarless gum or hard candy; Decrease dose</td>
<td>Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>Orthostatic Hypotension: Teach Pt. how to change posture slowly; Increase hydration; Decrease dose</td>
<td>Cardiology consult; Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Slightly Prolonged QTc Interval (&gt;450 ≤ 500Msecs): Repeat EKG; Decrease dose</td>
<td>Cardiology consult; Discontinue AP/MS; Switch AP with normal EKG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tachycardia: Cardiology consult; Decrease dose</td>
<td>Cardiology consult; Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Very Prolonged QTc Interval (&gt;500 Msecs): Discontinue AP; Repeat EKG; Cardiology consult</td>
<td>Switch AP with less QTc prolongation</td>
<td></td>
</tr>
<tr>
<td>Cognitive + Central Nervous Sys</td>
<td>Confusion: Assess for medical illness + illicit drug use; Decrease dose; Neurology consult</td>
<td>Obtain serum levels; Discontinue AP; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Headache: Add analgesic; Wait for improvement; Rule-out tension headache</td>
<td>Decrease dose; If there are problems with vision, neurology consult</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Memory Problems: Decrease dose</td>
<td>Neuro + neuropsychology consult; Meds at bedtime; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sedation/Hypersomnia: Give AP/MS at bedtime; Discontinue other sedating medications; Decrease dose</td>
<td>Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seizures: Get EEG; Neurology consult; Decrease AP dose; Switch AP; Increase MS dose</td>
<td>Discontinue AP/MS</td>
<td></td>
</tr>
<tr>
<td>Diabetes + Weight</td>
<td>Diabetes: Obtain fasting glucose + lipids at baseline, 3, and 6 months; Endocrine consult; Symptom-management education; Implement diet/exercise program</td>
<td>Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight Gain (developmentally inappropriate): Nutrition consult; Implement diet/exercise program; Monitor fasting glucose, cholesterol and triglycerides at baseline, 3, and 6 months</td>
<td>Switch AP/MS</td>
<td></td>
</tr>
<tr>
<td>Endocrine</td>
<td>Amenorrhea: Rule out pregnancy, hyperthyroidism + renal problems; Obtain prolactin levels</td>
<td>Gyn consult; Wait to see if resolves; Decrease dose; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Galactorrhea: Decrease dose; Obtain prolactin levels; Endocrine consult</td>
<td>Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gynecomastia (males): Obtain prolactin levels; Endocrine consult</td>
<td>Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperprolactinemia: No action needed unless clinical signs or symptoms, or PRL ≥ 280 mg/mL</td>
<td>Prolactin levels don’t need to be obtained in absence of symptoms</td>
<td></td>
</tr>
<tr>
<td>Extra-pyramidal Symptoms</td>
<td>Akathisia ¹: Decrease dose; Slow switch</td>
<td>Add beta adrenergic antagonist; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Akinesia ²: Decrease dose</td>
<td>Add anticholinergic; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dystonia ²: Add anticholinergic (IM); Add lorazepam (IM); Add antihistamine (IM)</td>
<td>Decrease dose; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Muscle Rigidity ²,³: Add anticholinergic; Decrease dose</td>
<td>Add dopamine agonist; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tardive Dyskinesia ³: Neurology consult; Discontinue AP; Increase dose</td>
<td>Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tremor ⁴: Decrease dose</td>
<td>Add anticholinergic; Switch AP</td>
<td></td>
</tr>
<tr>
<td>Medically Life-threatening</td>
<td>Agranulocytosis: Discontinue AP immediately; Emergency internal med/pediatric consult; Labs</td>
<td>Switch AP once agranulocytosis resolves</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Granulocytopenia: Discontinue AP; Pediatric consult; Repeat labs</td>
<td>Switch AP once ANC + WBC returns to normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukopenia Increase: Internal med/pediatric consult; Repeat labs; Consider discontinuing AP</td>
<td>Discontinue AP; Switch to different AP once LFTs are normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decreased libido; Erectile dysfunction: Decrease dose; Discontinue medications with sexual side-effects</td>
<td>Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enuresis: Void before sleep; Decrease fluids in evenings; Decrease dose; Give meds early in the evening; Wake youth to void at night</td>
<td>Use behavior intervention; Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypersalivation: Decrease dose; Teach Pt. to sleep in lateral decubitus position; Put towel over pillow</td>
<td>Switch AP; IF caused by EPS, add anticholinergic; IF caused by Clozapine, add alpha agonist (eg. Guanfacine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Insomnia: Evaluate for depression or anxiety disorder and treat underlying condition; Give total or larger AP dose at bedtime; Add hypnotic sleep aid; If due to AP, consider decreasing dose</td>
<td>Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nausea/Vomiting: Wait 1-2 days; Decrease dose; Add temporary antiemetic</td>
<td>Switch AP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rash: Discontinue AP; Dermatology consult if severe</td>
<td>Switch AP/MS once rash resolves</td>
<td></td>
</tr>
</tbody>
</table>


Notes: Use of more than one AP increases risk for AP-related side-effects. For further recommendations, please see Appendix for handouts, rating scales and additional guidelines for the management of side-effects.

FOOTNOTES:

¹ = Barnes Akathisia Rating Scale  
² = Simpson Angus Scale  
³ = Abnormal Involuntary Movement Scale  
⁴ = Antipsychotic  
MS = Mood Stabilizer
MEDICATION MAINTENANCE + DISCONTINUATION

CLINICAL PEARLS OF SIDE EFFECT MANAGEMENT

- Follow guidelines for primary disorder (when available); initial medication treatment should target the underlying symptom(s)/disorder.
- If inadequate response, add an AP, try a different AP, or augment with a MS; use the recommended titration schedule + deliver an adequate medication trial before adjusting medication.
- Conduct side effect and metabolic assessments and laboratory tests that are clinically relevant, comprehensive, and based on established guidelines.
- Provide accessible information to parents/guardians about identifying + managing side effects.
- Use evidence-based strategies to prevent or minimize side effects.
- Collaborate with medical or mental health specialists as needed.
- Follow general rules and clinical pearls for switching psychotropic medications (see below).

MINIMIZING SIDE EFFECTS WHEN SWITCHING PSYCHOTROPIC MEDICATIONS

- Start low! Go slow! And stop slowly! Avoid abrupt stopping, starting, and/or switching to reduce risk of rebound and withdrawal phenomena.
- Do not switch until the primary disorder has been treated according to target disorder guidelines at adequate dose and duration.
- Only stop and/or switch abruptly if a serious adverse effect necessitates it (i.e. severe neutropenia; agranulocytosis; diabetic ketoacidosis; neuroleptic malignant syndrome; acute pancreatitis; lithium toxicity; Stevens Johnson Syndrome; etc.).
- Slow switch using cross-titration is the preferred method; an even slower switch can be done using the plateau-cross titration method, with therapeutic dose overlap of medications (when switching to a less sedating or cholinergic medication, or one with a much longer half-life).
- If time permits, do not reduce the first medication by more than 25-50% per 5 half-lives.

ADDITIONAL CONSIDERATIONS

- When switching medications, the more different the binding affinity for the same receptor (between the two drugs), the greater the risk for side effects and rebound and withdrawal phenomena (esp. sedating; anti-cholinergic; dopaminergic).
- The more different the half-life of the medications with the same physiological effect (desired or undesired), the greater the risk for rebound and withdrawal phenomena; withdrawal and rebound phenomena are most likely when discontinuing from a short half-life medication.
- Withdrawal and rebound phenomena are mostly likely to occur when switching from a strongly anti-histaminergic (sedating) or anti-cholinergic medication (i.e., Clozapine, Olanzapine, Quetiapine), to a less strong binding medication (i.e., haloperidol, molindone, peridone, paliperidone, aripiprazole, Ziprasidone); or from a strongly binding anti-dopaminergic (i.e. FGA AP, Risperidone Paliperidone) to a less strongly binding antipsychotic (i.e., clozapine,quetiapine, clozapine); or a full antagonist, to a partial agonist (aripiprazole).
- Insufficient efficacy or increased side effects may occur during a switch when medications metabolized by cytochrome P450 liver enzymes are paired with a medication that affects that same enzyme.
- Never discontinue Lithium or Clozapine abruptly to avoid potentially severe rebound of mania or psychoses.
- Quetiapine and Mirtazapine can lead to more sedation at lower doses (below 250-300 mg for Quetiapine, and below 30 mg for Mirtazapine).
APPENDIX

Algorithm for the Treatment of ADHD with Comorbid Aggression

Algorithm for the Treatment of Depression/Anxiety with Comorbid Aggression


Action Plans: Tips for Families

Dietary and Physical Activity Recommendations

AP Side Effects Checklist

Clinical Global Impressions (CGI)

Brief Psychiatric Rating Scale for Children (BPRS-C-9)

Modified Overt Aggression Scale (MOAS)

Young Mania Rating Scale
ALGORITHM FOR THE TREATMENT OF ADHD WITH COMORBID AGGRESSION

STAGE 0
THOROUGH EVAL, DIAGNOSTIC ASSESSMENT AND FAMILY CONSULTATION RE: TREATMENT ALTERNATIVES
NON-MEDICATION TREATMENT ALTERNATIVES

STAGE 1
ESTABLISH PRESENCE OF ADHD, BEGIN ADHD ALGORITHM

STAGE 2
ADD A BEHAVIORAL INTERVENTION** *

STAGE 3
ADD ANTIPSYCHOTIC** TO THE STIMULANT*** *

STAGE 4
ADD LITHIUM OR DIVALPROEX SODIUM TO THE REGIMEN *

STAGE 5
ADD AGENT NOT USED IN STAGE FOUR *
CLINICAL CONSULTATION

CONTINUATION
MAINTENANCE

FOOTNOTES:
* Evaluate adequacy of behavior treatment after inadequate response at any stage.
** Risperidone has the most efficacy and safety data for any AP (antipsychotic) in children.
*** If patient is an imminent threat to self or others, antipsychotics may be started with behavioral treatment.
⁺ Primary care physicians (PCP)s may choose to obtain psychiatric consultation (either at this step, or prior to), depending on level of experience, training and comfortability.

Note: Any stage can be skipped depending on the clinical picture.

Adapted from: Pliszka, SR, Crismon, M.L., Hughes, CW, Connors CK et al. 2006.
ALGORITHM FOR THE TREATMENT OF DEPRESSION/ANXIETY WITH COMORBID AGGRESSION

THOROUGH EVAL, DIAGNOSTIC ASSESSMENT AND FAMILY CONSULTATION RE: TREATMENT ALTERNATIVES

GIVEN DX OF MDD OR ANX D/O, BEGIN ALGORITHM (INCLUDING CBT AND/OR SSRI)

ADD A BEHAVIORAL INTERVENTION* * (IN ADDITION TO CBT & SSRI)

ADD LITHIUM OR DIVALPROEX SODIUM TO THE SSRI*

ADD ANTIPSYCHOTIC TO THE SSRI*** *

ALTERNATE CLASS (VEN, BUP, MRT, DXT*)

REASSESS TREATMENT GUIDANCE

ADD AGENT NOT USED IN STAGE FOUR *

CLINICAL CONSULTATION

NON-MEDICATION TREATMENT ALTERNATIVES

CONTINUATION

CONTINUATION

CONTINUATION

CONTINUATION

CONTINUATION

CONTINUATION

CONTINUATION

MAINTENANCE

FOOTNOTES

¹ Evidence-based psychotherapy can be used at any stage in the algorithm.
² FLX (Fluoxetine) is the only antidepressant with an FDA-approved indication for depression in youth.
³ SSRI = Selective Serotonin Reuptake Inhibitor (includes: FLX (Fluoxetine); CIT (Citalopram); SRT (Sertraline); EST (Escitalopram); Paroxetine (not rec. for pre-adolescents);
⁴ VEN = Venlafaxine; BUP = Bupropion; DXT = Duloxetine, MRT = Mirtazapine
⁵ Primary care physicians (PCPs) may choose to obtain psychiatric consultation (either at this step, or prior to), depending on experience, training and comfort, level

Note: Any stage can be skipped depending on the clinical picture.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADDRESSING NEEDS + IDENTIFYING RESOURCES</strong></td>
<td>How will the need(s) be addressed?</td>
<td>Who is the active agent?</td>
<td>Is treatment location- and time specific?</td>
<td>What is the time-frame?</td>
<td>How many sessions of therapy are suggested?</td>
<td>Why is the action important?</td>
</tr>
<tr>
<td></td>
<td>What resources are available?</td>
<td>Who is accountable?</td>
<td>Type of environment?</td>
<td>How frequent are sessions?</td>
<td>What is the Rx dose?</td>
<td>Targeting which symptom(s)? Short-term goals? Objectives?</td>
</tr>
<tr>
<td><strong>SOCIAL + EMOTIONAL:</strong></td>
<td><strong>WHAT?</strong></td>
<td><strong>WHO?</strong></td>
<td><strong>WHERE?</strong></td>
<td><strong>WHEN?</strong></td>
<td><strong>HOW MUCH?</strong></td>
<td>Developing a skill or hobby can increase interest, dedication, feelings of accomplishment, and a positive sense of self-worth.</td>
</tr>
<tr>
<td>IMPROVING SELF-ESTEEM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Having friends builds self-esteem, and creates more positive social interactions. Consider planning activities with other students.</td>
</tr>
<tr>
<td>MAKING FRIENDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MEDICAL NEEDS:</strong></td>
<td><strong>WHAT?</strong></td>
<td><strong>WHO?</strong></td>
<td><strong>WHERE?</strong></td>
<td><strong>WHEN?</strong></td>
<td><strong>HOW MUCH?</strong></td>
<td></td>
</tr>
<tr>
<td>MAKING THE MOST OF MEDICINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Finding the best type and dose of medication will result in fewer or no side-effects, and improve overall physical, social and mental well-being.</td>
</tr>
<tr>
<td>MONITORING SIDE-EFFECTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Monitoring side-effects will help you to discern whether or not medication is working for your child.</td>
</tr>
<tr>
<td><strong>EDUCATIONAL NEEDS:</strong></td>
<td><strong>WHAT?</strong></td>
<td><strong>WHO?</strong></td>
<td><strong>WHERE?</strong></td>
<td><strong>WHEN?</strong></td>
<td><strong>HOW MUCH?</strong></td>
<td>Understanding your child’s apprehension, perceived hardships, and attitudes toward learning can help you find new ways to make learning more fun.</td>
</tr>
<tr>
<td>PERFORMANCE IN SCHOOL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Doing and finishing homework prepares child for more success the next day at school, and on tests and final grades.</td>
</tr>
<tr>
<td>DOING HOMEWORK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-------</td>
<td>-----------</td>
<td>------</td>
</tr>
<tr>
<td>CHILD IN TREATMENT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Raising a child that requires special attention and additional time, especially when there are other children in the family, can be difficult on everyone.</td>
</tr>
<tr>
<td>PARENTS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Strong intra-family communication is key to maintenance + progress.</td>
</tr>
<tr>
<td>SIBLINGS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Including everyone in the action plans, spending individual time with family members, and taking time for yourself, is key to decreasing conflicts in the home, and preventing feelings of negligence, burnout or burden.</td>
</tr>
<tr>
<td>FAMILY AS A WHOLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Note: This chart is helpful in that it provides examples of how to establish short-term, intermediate, and long-term outcomes and goals with the child and family. This form can be copied for repeated use.
ACTION PLANS: TIPS FOR FAMILIES

Far too often, the systems in place to help children with aggression fall short, largely because the unique problems of an individual child require costly, time-consuming attention, and the number of individual kids needing such care exceeds the capacity of available resources. The template for Action Plans provide a framework useful for both younger and older children; this template can be used together with psychosocial interventions, and can be tailored depending on the needs of your child and the environment in which the Action Plan template is being used.

PRINCIPLES OF ACTION FOR THE PARENT

- Even with a relatively treatable condition such as asthma, in addition to carefully monitoring your child’s medications, you must ensure that babysitters, teachers and relatives know what to do if your child has an “attack” and you are not there. Now, think about the kinds of steps you must take to prevent your child’s exposure to potential triggers that can set off an attack (house dust, pollens, or pets). The same kind of planning is needed to anticipate or prevent your child’s reactions to aggression “triggers”.

- Show warmth and acceptance to your child despite his/her flaws, identify available resources to help you, prioritize short, intermediate and long-term goals, plan action steps that are truly feasible, and commit yourself to small changes first, then building upon them.

- Remember when you are feeling overwhelmed by the lack of available resources, time pressures and conflicting priorities, take into account the child’s capabilities and input, and your strengths and weaknesses as a parent. Don’t be hard on yourself...or your child. Patient, long-term approaches will usually succeed, but demands for big results immediately will overwhelm both you and your child.

- As a parent, think of yourself as the skipper on a sailing vessel. At the beginning of a voyage, your craft should at minimum be outfitted with sails, a rudder, a compass, map, a radio, a knowledgeable crew, and adequate provisions. Even with all of these necessities on board, and despite that you charted a thoughtful course at the outset, any significant change in weather is likely to dictate a change in plans. Adapting to prevailing winds and adjusting course are minimum revisions, but more dramatically, you may need to weigh anchor temporarily in a safe harbor, return to port, or even radio for help! Remember that flexibility will assist you in finding the most perfect solution. Don’t set yourself up for failure; rather, recognize that though missteps are likely to happen, you can eventually achieve success if you keep at it, working your plan, and patiently revising it when needed.

- Developing and implementing a plan for your child (and for yourself and family) will help you to be able to step back and reflect as often as needed, giving you the ability to explore new options and make necessary mid-course corrections.

- Planning won’t solve all of your problems, but it certainly will help you be prepared for the challenges ahead; it’s better to empower yourself by taking charge, rather than letting yourself become overwhelmed by your child’s aggression or by the challenges in getting help from your child’s school or healthcare system.
# Dietary and Physical Activity Recommendations for Children and Adolescents on Psychotropic Agents

## Target Management Strategies

<table>
<thead>
<tr>
<th><strong>Age Group</strong></th>
<th>Pediatric patients &lt;18 years receiving psychotropic medications associated with weight gain.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parenting Style</strong></td>
<td>Allow child to self-regulate meals; encouraging authoritative parenting style supporting increased physical activity and reduced sedentary behavior, providing tangible and motivational support; discourage overly restrictive parenting style.</td>
</tr>
<tr>
<td><strong>Family Involvement</strong></td>
<td>Yes; it is very important to have support.</td>
</tr>
<tr>
<td><strong>Sugar-sweetened Beverages</strong></td>
<td>Replace sugar-sweetened drinks, including “diet” drinks, with water, or moderate amounts of unsweetened tea or low-fat milk (no sugar-sweetened beverages if overweight or obese), assess for excessive consumption of 100% fruit juice.</td>
</tr>
<tr>
<td><strong>Meal Frequency</strong></td>
<td>Assess for meal frequency (including quality), aim for 3 to less than 6 separate meals per day, with no more than 1 meal in the evening or at night.</td>
</tr>
<tr>
<td><strong>Breakfast</strong></td>
<td>Daily breakfast.</td>
</tr>
<tr>
<td><strong>Meal Portions</strong></td>
<td>Assess for consumption of excessive portion sizes for age, promote serving small meal portions.</td>
</tr>
<tr>
<td><strong>Pacing of Food Consumption</strong></td>
<td>Eat slowly and take second helpings only after a delay of 15-20 minutes.</td>
</tr>
<tr>
<td><strong>Sugar Content</strong></td>
<td>Assess for excessive consumption of foods that are high in energy density, preferentially eat food with a low glycemic index.</td>
</tr>
<tr>
<td><strong>Fat Content</strong></td>
<td>Diet with balanced macronutrients (calories from fat, complex carbohydrates, and protein in proportions for age recommended by Dietary Reference Intakes); Reduce saturated fat intake, but avoid extensive consumption of processed fat-free food items.</td>
</tr>
<tr>
<td><strong>Fiber Content</strong></td>
<td>Diet high in fiber (25-30 grams/day); five or more servings of fruits and vegetables per day (avoid fruit juice).</td>
</tr>
<tr>
<td><strong>Snacks</strong></td>
<td>Assess for snacking patterns (including quality); Avoid snacking in a satiety state, replacing high-fat, high-calorie snacks with fruit and vegetables.</td>
</tr>
<tr>
<td><strong>Outside Meals / Fast Food</strong></td>
<td>Limit meals outside the home, especially in fast-food restaurants (no more than once per week); family meals at least 5-6 times/week.</td>
</tr>
<tr>
<td><strong>Sedentary Behavior</strong></td>
<td>Two or fewer hours of screen time per day, and no television or videogames in the room where the child sleeps.</td>
</tr>
<tr>
<td><strong>Exercise</strong></td>
<td>Perform moderate level physical activity for at least 30-60 minutes/day.</td>
</tr>
</tbody>
</table>


**AP SIDE-EFFECTS CHECKLIST**

Patient: ___________________________ Date: ___________________________

Rater: ___________________________

**INSTRUCTIONS**

Rate the severity of the following side-effects from 0 (not present) to 3 (severe). Side-effects marked with a † should be scored using only 0 (not present) or 1 (present).

**ANCHORS**

<table>
<thead>
<tr>
<th>Rating</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None = Mild</td>
</tr>
<tr>
<td>1</td>
<td>Moderate</td>
</tr>
<tr>
<td>2</td>
<td>Severe</td>
</tr>
<tr>
<td>N/A</td>
<td>Not Assessed</td>
</tr>
</tbody>
</table>

**LIFE-THREATENING**

†NMS* ________
Decreased ANC* ________
†Agranulocytosis ________
Marked Increase in LFTs* ________

**EPS**

Tardive Dyskinesia ________
Akathisia ________
Akinesia ________
Tremor ________
Muscle Rigidity ________
†Dystonia ________
Tardive Dyskinesia ________

**COGNITIVE EFFECTS**

Confusion ________
Memory Problems ________
Sedation ________
Hypersomnia ________
Insomnia ________
Headache ________

**CARDIAC**

QTc Prolongation ________
Tachycardia ________
Hypotension ________

* Abbreviations

NMS = Neuroleptic malignant syndrome
LFTs = Liver function tests
ANC = Absolute neutrophil count

**WEIGHT AND DIABETES**

Current Height ________ inches
Baseline Weight ________ pounds
Current Weight ________ pounds
Weight Gain ________ pounds
Baseline BMI Percentile ________
Current BMI Percentile ________
Elevated Glucose ________
Elevated Cholesterol ________
Elevated Triglycerides ________

**ENDOCRINE**

†Amenorrhea ________
†Galactorrhea ________
†Gynecomastia ________
Excess Thirst ________
Unexplained Weight Loss ________

**ANTICHOLINERGIC**

Dry Mouth ________
Blurred Vision ________
Constipation ________

**OTHER**

Irritability ________
Nausea/Vomiting ________
Sexual Dysfunction ________
Decreased Libido ________
Dermatological ________
Hypersalivation ________
Enuresis ________
CLINICAL GLOBAL IMPRESSIONS (CGI)

Patient:                                      Date:

Rater:

INSTRUCTIONS

The CGI helps quantify the overall severity and improvement of a patient’s condition. Rate the patient’s severity of illness and global improvement using the anchors below.

SEVERITY OF ILLNESS

How ill is the patient at this time?

- Normal, not at all ill
- Borderline mentally ill
- Mildly ill
- Moderately ill
- Markedly ill
- Severely ill
- Among the most extremely ill patients

GLOBAL IMPROVEMENT

Compared to the patient’s condition prior to treatment, how ill is he/she now?

- Very much improved
- Much improved
- Minimally improved
- No change
- Minimally worse
- Much worse
- Very much worse
DESCRIPTION
The BPRS-C (9-item version) can be used to screen for and monitor a variety of psychiatric symptoms. Item descriptions are presented below, along with anchors to guide how the severity of each item is rated.

ANCHORS
Items are rated using the following scale:

0 = Not Present  1 = Very Mild  2 = Mild  3 = Moderate  4 = Moderate-Severe  5 = Severe  6 = Very Severe

___ 1. UNCOOPERATIVE:
NEGATIVE, UNCOOPERATIVE, RESISTANT, DIFFICULT TO MANAGE
Not Present: Cooperative, pleasant.
Mild: Occasionally refuses to comply with rules and expectations, in only 1 situation/setting.
Moderate-Severe: Persistent failure to comply with rules/expectations in more than 1 setting. Causes frequent impairment in functioning.
Extremely Severe: Constantly refuses to comply with rules and expectations, delinquent behaviors, running away. Causes severe impairment in functioning in most situations/settings.

___ 2. HOSTILITY:
ANGRY OR SUSPICIOUS AFFECT, BELLIGERENCE, ACCUSATIONS AND VERBAL CONDEMNATION OF OTHERS
Not Present: Cooperative, pleasant.
Mild: Occasionally sarcastic, loud, guarded, quarrelsome. Causes mild dysfunction in one situation or setting.
Moderate-Severe: Causes frequent impairment in several situations/settings.
Extremely Severe: Assaultive, destructive. Causes severe impairment in functioning in most situations/settings.

___ 3. MANIPULATIVENESS:
LYING, CHEATING, EXPLOITIVE OF OTHERS
Not Present: Not at all.
Mild: Occasionally gets in trouble for lying, may cheat on occasions.
Moderate-Severe: Frequently lies/cons/manipulates people he knows. Causes frequent impairment in functioning in several situations/settings.
Extremely Severe: Constantly relates to others in an exploitive/manipulative manner, cons strangers out of money/situations. Causes severe impairment in functioning in most situations/settings.

___ 4. DEPRESSIVE MOOD:
SAD, TEARFUL, DEPRESSIVE DEMEANOR
Not Present: Occasionally/quickly disappears.
Mild: Sustained periods/excessive for event.
Moderate-Severe: Unhappy most time/no precipitant.
Extremely Severe: Unhappy all time/psychic pain. Causes severe impairment in functioning.

___ 5. FEELINGS OF INFERIORITY:
LACKING SELF-CONFIDENCE/SELF-DEPRECIATORY

Not Present: Feels good/positive about self.
Mild: Occasionally feels not as good as others/deficits in 1 area.
Moderate-Severe: Feels others are better than they are. Gives negative, bland answers, can’t think of anything good about themselves.
Extremely Severe: Constantly feels others are better. Feels worthless/not lovable.

6. HYPERACTIVITY:
EXCESSIVE ENERGY EXPENDITURE, FREQUENT CHANGES IN POSTURE, PERPETUAL MOTION

Not Present: Slight restlessness, fidgeting. No impact on functioning.
Mild: Occasional restlessness, fidgeting, frequent changes of posture. Noticeable, but does not cause impairment in functioning.
Moderate-Severe: Excessive energy, movement, cannot stay still or seated. Causes dysfunction on numerous occasions/situations. Seeks help for behaviors.
Extremely Severe: Continuous motor excitement, cannot be stilled. Causes major interference in functioning on most occasions/situations.

7. Distractibility:
POOR CONCENTRATION, SHORTENED ATTENTION SPAN, REACTIVITY TO PERIPHERAL STIMULI

Not Present: Performance consistent with ability.
Mild: Occasionally daydreams, easily distracted. Can be relaxed or reassured.
Moderate-Severe: Frequently has trouble concentrating, avoids mental tasks, disruptive. Needs frequent assistance to stay focused. Causes decreased performance.
Extremely Severe: Constant, needs 1:1 assistance to stay focused.

8. Tension:
NERVOUSNESS, FIDGETINESS, NERVOUS MOVEMENTS OF HANDS OR FEET

Not Present: Not at all.
Mild: Occasionally feels nervous or fidgets. Can be relaxed or reassured.
Moderate-Severe: Most days/time feels nervous/fidgety. Causes mental or physical distress.
Extremely Severe: Pervasive and extreme nervousness, fidgeting, nervous movements of hands and/or feet.

9. Anxiety:
CLINGING BEHAVIOR, SEPARATION ANXIETY, PREOCCUPATION WITH ANXIETY TOPICS, FEARS OR PHOBIAS

Not Present: Not at all.
Mild: Occasionally worries (at least 3 times a week) about anticipated/current events, separation, fears, or phobias. These worries appear excessive for situation.
Moderate-Severe: Most days/time worries about at least 2 life circumstances, or anticipated/current events.
Extremely Severe: Pervasive and extreme worry about most everything, real or imagined.

TOTAL SCORE FOR ALL 9 ITEMS

*Reprinted with permission from the author (Hughes et al., 2003–2004).
**MODIFIED OVERT AGGRESSION SCALE (MOAS)**

**INSTRUCTIONS AND SCORING SUMMARY: CATEGORY SUM SCORE WEIGHTS WEIGHTED SUM**

The MOAS helps clinical interviewers track aggressive incidents in outpatient settings. Rate the patient's aggressive behavior over the past week. Select as many items as are appropriate. 1) Add items within each category; 2) In the scoring summary, multiply sum by weight and add all the weighted sums for total weighted score. Use this score to track changes in level of aggression over time.

**VERBAL AGGRESSION: VERBAL HOSTILITY, STATEMENTS OR INVECTIVES THAT SEEK TO INFLECT PSYCHOLOGICAL HARM ON ANOTHER THROUGH DEVALUATION/DEGRADATION, AND THREATS OF PHYSICAL ATTACK**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>__</td>
<td>0. No verbal aggression</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>1. Shouts angrily, curses mildly, or makes personal insults</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>2. Curses viciously, is severely insulting, has temper outbursts or deliberately (e.g., to gain money or sex)</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>3. Impulsively threatens violence toward others or self</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>4. Threatens violence toward others or self repeatedly</td>
<td></td>
</tr>
</tbody>
</table>

**SUM VERBAL AGGRESSION SCORE**

**AGGRESSION AGAINST PROPERTY: WANTON AND RECKLESS DESTRUCTION OF WARD PARAPHERNALIA OR OTHERS’ POSSESSIONS**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>__</td>
<td>0. No aggression against property</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>1. Slams door angrily, rips clothing, urinates on floor</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>2. Throws objects down, kicks furniture, defaces walls</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>3. Breaks objects, smashes windows</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>4. Sets fires, throws objects dangerously</td>
<td></td>
</tr>
</tbody>
</table>

**SUM PROPERTY AGGRESSION SCORE**

**AUTOAGGRESSION: PHYSICAL INJURY TOWARD ONESELF, SELF-MUTILATION, OR SUICIDE ATTEMPT**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>__</td>
<td>0. No autoaggression</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>1. Picks or scratches skin, pulls hair out, hits self (without injury)</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>2. Bangs head, hits fists into walls, throws self on floor</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>3. Inflicts minor cuts, bruises, burns, or welts on self</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>4. Inflicts major injury on self or makes a suicide attempt</td>
<td></td>
</tr>
</tbody>
</table>

**SUM AUTOAGGRESSION SCORE**

**PHYSICAL AGGRESSION: VIOLENT ACTION INTENDED TO INFLECT PAIN, BODILY HARM, OR DEATH**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>__</td>
<td>0. No physical aggression</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>1. Makes menacing gestures, swings at people, grabs at clothing</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>2. Strikes, pushes, scratches, pulls hair of others (without injury)</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>3. Attacks others, causing mild injury (bruises, sprains, welts, etc.)</td>
<td></td>
</tr>
<tr>
<td>__</td>
<td>4. Attacks others, causing serious injury (fracture, loss of teeth, deep cuts, loss of consciousness, etc.)</td>
<td></td>
</tr>
</tbody>
</table>

**SUM PHYSICAL AGGRESSION SCORE**

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>SUM SCORE</th>
<th>WEIGHTS</th>
<th>WEIGHTED SUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verbal Aggression</td>
<td></td>
<td>X1</td>
<td></td>
</tr>
<tr>
<td>Aggression Against Property</td>
<td></td>
<td>X2</td>
<td></td>
</tr>
<tr>
<td>Autoaggression</td>
<td></td>
<td>X3</td>
<td></td>
</tr>
<tr>
<td>Physical Aggression</td>
<td></td>
<td>X4</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL WEIGHTED SCORE**

YOUNG MANIA RATING SCALE*

Patient: Date: 

Rater:

INSTRUCTIONS
The purpose of each item is to rate the severity of that abnormality in the patient. When several keys are given for the grade of severity, the presence of only 1 is required to qualify for that rating.
The keys provided are guides. One can ignore the anchors if that is necessary to indicate severity, although this should be the exception rather than the rule. This is particularly useful when the severity of a particular item in a patient does not follow the progression indicated by the anchors.

ELEVATED MOOD
0 = Absent
1 = Mildly or possibly increased on questioning
2 = Definite subjective elevation; optimistic, self-confident; cheerful; appropriate to content
3 = Elevated, inappropriate to content; humorous
4 = Euphoric; inappropriate laughter; singing

INCREASED MOTOR ACTIVITY/ENERGY
0 = Absent
1 = Subjectively increased
2 = Animated; gestures increased
3 = Excessive energy; hyperactive at times; restless (can be calmed)
4 = Motor excitement; continuous hyperactivity (cannot be calmed)

SEXUAL INTEREST
0 = Normal; not increased
1 = Mildly or possibly increased
2 = Definite subjective increase on questioning
3 = Spontaneous sexual content; elaborates on sexual matters; hypersexual by self-report
4 = Overt sexual acts (toward patients, staff, or interviewer)

SLEEP
0 = Reports no decrease in sleep
1 = Sleeping less than normal amount by up to one hour
2 = Sleeping less than normal by more than one hour
3 = Reports decreased need for sleep
4 = Denies need for sleep

IRRITABILITY
0 = Absent
2 = Subjectively increased
4 = Irritable at times during interview; recent episodes of annoyance or anger on ward
6 = Frequently irritable during interview; short, curt throughout
8 = Hostile, uncooperative; interview impossible
SPEECH (RATE AND AMOUNT)
0 = No increase
2 = Feels talkative
4 = Increased rate or amount at times, verbose at times
6 = Push; consistently increased rate and amount; difficult to interrupt
8 = Pressured; uninterruptible; continuous speech

LANGUAGE/THOUGHT DISORDER
0 = Absent
1 = Circumstantial; mild distractibility; quick thoughts
2 = Distractible; loses goal of thought; changes topics frequently; racing thoughts
3 = Flight of ideas; tangentiality; difficult to follow; rhyming, echolalia
4 = Incoherent; communication impossible

THOUGHT CONTENT
0 = Normal
2 = Questionable plans, new interests
4 = Special projects; hyperreligious
6 = Grandiose or paranoid ideas; ideas of reference
8 = Delusions, hallucinations

DISRUPTIVE/AGGRESSIVE BEHAVIOR
0 = Absent, cooperative
2 = Sarcastic; loud at times, guarded
4 = Demanding; threats on ward
6 = Threatens interviewer; shouting; interview difficult
8 = Assaultive; destructive; interview impossible

APPEARANCE
0 = Appropriate dress and grooming
1 = Minimally unkempt
2 = Poorly groomed; moderately disheveled; overdressed
3 = Disheveled; partly clothed; garish makeup
4 = Completely unkempt; decorated; bizarre garb

INSIGHT
0 = Present; admits illness; agrees with need for treatment
1 = Possibly ill
2 = Admits behavior change, but denies illness
3 = Admits possible change in behavior, but denies illness
   Denies any behavior change

TOTAL SCORE _______________________
(0–13 = minimal severity; 14–20 = mild; 21–26 = moderate; 27–38 = severe)

BIBLIOGRAPHY


Correll CU: From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. European Psychiatry. – in press


